Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2018

Open Access 01-12-2018 | Study protocol

Pregabalin versus placebo in targeting pro-nociceptive mechanisms to prevent chronic pain after whiplash injury in at-risk individuals – a feasibility study for a randomised controlled trial

Authors: J. Nikles, G. Keijzers, G. Mitchell, S. Schug, R. Ware, S. A. McLean, L. Connelly, S. Gibson, S. F. Farrell, M. Sterling

Published in: Trials | Issue 1/2018

Login to get access

Abstract

Background

Whiplash-associated disorders (WAD) are an enormous and costly burden to Australian society. Up to 50% of people who experience a whiplash injury will never fully recover. Whiplash is resistant to treatment and no early management approach has yet been shown to prevent chronic pain. The early presence of central sensitization is associated with poor recovery. Pregabalin’s effects on central sensitization indicate the potential to prevent or modulate these processes after whiplash injury and to improve health outcomes, but this has not been investigated. This paper describes the protocol for a feasibility study for a randomised controlled trial of pregabalin plus evidence-based advice compared to placebo plus evidence-based advice for individuals with acute whiplash injury who are at risk of poor recovery.

Methods

This double blind, placebo-controlled randomised feasibility study will examine the feasibility and potential effectiveness of pregabalin and evidence-based advice (intervention) compared to placebo and evidence-based advice (control) for individuals with acute whiplash injury at risk of poor recovery. Thirty participants (15 per group) aged 18–65 years with Grade II WAD, within 48 hours of injury and currently experiencing at least moderate pain (NRS: ≥ 5/10) will be recruited from Emergency Departments of public hospitals in Queensland, Australia. Pregabalin will be commenced at 75 mg bd and titrated up to 300 mg bd as tolerated for 4 weeks followed by 1 week of weaning.

Results

The feasibility of trial procedures will be tested, as well as the potential effect of the intervention on the outcomes. The primary outcome of neck pain intensity at 3 months from randomisation will be compared between the treatment groups using standard analysis of variance techniques.

Discussion

Feasibility and potential effectiveness data will inform an appropriately powered full trial, which if successful, will provide an effective and cost-effective intervention for a costly and treatment resistant condition. It will also have implications for the early management of other traumatic conditions beyond whiplash.

Trial registration

Clinical Trials Primary Registry: Australian and New Zealand Clinical Trials Registry.
Clinical Trial Registration Number: ACTRN12617000059​369.
Date of Registration: 11/01/2017.
Primary Trial Sponsor: The University of Queensland, Brisbane QLD 4072 Australia.
Appendix
Available only for authorised users
Literature
1.
Berglund A, Alfredsson L, Jensen I, Bodin L, Nygren A. Occupant- and crash-related factors associated with risk of whiplash injury. Ann Epidemiol. 2003;13:66–72.CrossRefPubMed
2.
Niska R, Bhuiya F, Xu J. National Hospital Ambulatory Medical Care Survey: 2007 emergency department summary. Natl Health Stat Report. 2010;26:1–31.
3.
Connelly LB, Supangan R. The economic costs of road traffic crashes: Australia, states and territories. Accid Anal Prev. 2006;38:1087–93.CrossRefPubMed
4.
Holm LW, Carroll LJ, Cassidy JD, et al. The burden and determinants of neck pain in Whiplash associated disorders after traffic collisions, results of the Bone and Joint Decade 2000–2010 Task Force on Neck pain and its Associated Disorders. Spine. 2008;33(4 Suppl):S52–9.CrossRefPubMed
5.
Carroll L, et al. Course and prognostic factors for neck pain in WAD. Spine. 2008;33:583–92.
6.
Sterling M, Hendrikz J, Kenardy J. Compensation claim lodgement and health outcome developmental trajectories following whiplash injury: A prospective study. Pain. 2010;150(1):22–8.CrossRefPubMed
7.
Casey PP, Feyer AM, Cameron ID. Course of recovery for whiplash associated disorders in a compensation setting. Injury. 2015;46(11):2118–29.CrossRefPubMed
8.
State Insurance Regulatory Authority: Guidelines for the management of acute whiplash-associated disorders – for health professionals, third edition. Sydney: 2014.
9.
Southerst D, Nordin MC, Cote P, et al. Is exercise effective for the management of neck pain and associated disorders or whiplash-associated disorders? A systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Spine J. 2016;16(12):1503–23.CrossRefPubMed
10.
Wiangkham T, Duda J, Haque S, Madi M, Rushton A. The effectiveness of conservative management for acute whiplash associated disorder (WAD) II: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2015;10(7):e0133415.CrossRefPubMedPubMedCentral
11.
Teasell R, McClure J, Walton D, et al. A research synthesis of therapeutic interventions for whiplash-associated disorder (WAD): part 2 - interventions for acute WAD. Pain Res Manage. 2010;15(5):295–304.CrossRef
12.
Jull G, Kenardy J, Hendrikz J, Cohen M, Sterling M. Management of acute whiplash: A randomized controlled trial of multidisciplinary stratified treatments. Pain. 2013;154:1798–806.CrossRefPubMed
13.
Jull G, et al. Towards optimal early management after whiplash injury to lessen the rate of transition to chronicity. Spine. 2011;36:s275–87.CrossRef
14.
Sterling M, Carroll LJ, Kasch H, Kamper SJ, Stemper B. Prognosis after whiplash injury: where to from here? Discussion paper 4. Spine (Phila Pa 1976). 2011;36(25 Suppl):S330–4.CrossRef
15.
Nikles J, Yelland M, Bayram C, Miller G, Sterling M. Management of whiplash associated disorders in Australian general practice. BMC Musculoskelet Disord. 2017;18(1):551.
16.
Curatolo M. Pharmacological and interventional management of pain after whiplash injury. J Orthop Sports Phys Ther. 2016;46(10):845–50.CrossRefPubMed
17.
Walton D, Carroll L, Kasch H, et al. An overview of systematic reviews on prognostic factors in neck pain: Results from the International Collaboration on Neck Pain (ICON) project. Open Orthop J. 2013;7:494–505.CrossRefPubMedPubMedCentral
18.
Sterling M. Differential development of sensory hypersensitivity and a measure of spinal cord hyperexcitability following whiplash injury. Pain. 2010;150:501–6.CrossRefPubMed
19.
Jull G, Sterling M, Kenardy J, Beller E. Does the presence of sensory hypersensitivity influence outcomes of physical rehabilitation for chronic whiplash? - A preliminary RCT. Pain. 2007;129(2):28–34.CrossRefPubMed
20.
Dobbin M. Pharmaceutical drug misuse in Australia. Aust Prescr. 2014;37(3):79–81.CrossRef
21.
Beaudoin FL, Gutman R, Merchant RC, et al. Persistent pain after motor vehicle collision: comparative effectiveness of opioids vs nonsteroidal anti-inflammatory drugs prescribed from the emergency department-a propensity matched analysis. Pain. 2017;158(2):289–95.CrossRefPubMed
22.
Harris R, Napadow V, Huggins J, et al. Pregabalin rectifies aberrant brain chemistry, connectivity and functional response in chronic pain patients. Anesthesiology. 2013;119(6):1453–64.CrossRefPubMed
23.
Moore R, Staube S, Wiffen P, Derry S, McQuay H. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;3:CD007076.
24.
Mathieson S, Maher C, McLachlan A, et al. Trial of pregabalin for acute and chronic sciatica. N Engl J Med. 2017;376:1111–20.CrossRefPubMed
25.
Buvanendran A, et al. Perioperative oral pregablin reduces chronic pain after total knee arthroplasty: a prospective randomized controlled trial. Anesth Analg. 2010;110(1):199–207.CrossRefPubMed
26.
Burke S, Shorten G. Perioperative pregabalin improves pain and functional outcomes 3 months after lumbar discectomy. Anesth Analg. 2010;110:1180–5.PubMed
27.
28.
Eipe N, et al. Perioperative use of pregabalin for acute pain-a systematic review and meta-analysis. Pain. 2015;156:1284–300.CrossRefPubMed
29.
30.
Mishriky BM, et al. Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. Br J Anaesth. 2015;114:10–31.CrossRefPubMed
31.
Feltner D, et al. Efficacy of pregabalin in generalized social anxiety disorder. Int Clin Psychopharmacol. 2011;26:213–20.CrossRefPubMed
32.
Sterling M, Hendrikz J, Kenardy J. Similar factors predict disability and PTSD trajectories following whiplash injury. Pain 2011;152(6):1272–8.CrossRefPubMed
33.
34.
35.
Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284–92.CrossRefPubMed
36.
37.
38.
Siddall P, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial. Neurology. 2006;67:1792–800.CrossRefPubMed
39.
Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Safety. 2014;5:38–56.CrossRef
40.
Williamson A, et al. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14:798–804.CrossRefPubMed
41.
Vernon H, Mior S. The Neck Disability Index: a study of reliability and validity. J Manipulative Physiol Ther. 1991;14:409–15.PubMed
42.
Sullivan M, Bishop S, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7:524–32.CrossRef
43.
Foa E. Posttraumatic Stress Diagnostic Scale: Manual. Minneapolis: NCS Pearson; 1995.
44.
Lovibond S, Lovibond P. Manual for the Depression Anxiety Stress Scales. 2nd ed. Sydney: Psychology Foundation; 1995.
45.
Ware JE, Kosinski M, Keller SD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–33.CrossRefPubMed
46.
Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6(3):149–58.CrossRefPubMed
47.
Haldeman S, Carroll L, Cassidy D, Schubert J, Nygren A. The Bone and Joint Decade 2000– 2010. Task Force on Neck Pain and Its Associated Disorders. Eur Spine J. 2008;17 Suppl 1:5–7.CrossRef
48.
Gewandter JS, et al. Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain. 2015;156:1184–97.CrossRefPubMed
49.
50.
Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.CrossRefPubMed
51.
Goossens M, Rutten-van Mölken M, Vlaeyen J, van der Linden S. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol. 2000;53(7):688–95.CrossRefPubMed
52.
Brazier J, et al. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRefPubMed
53.
Norman R, et al. Valuing SF-6D health states using a discrete choice experiment. Med Decis Mak. 2014;34(6):773–86.CrossRef
54.
Ritchie C, Kenardy J, Smeets R, Sterling M. StressModEx--Physiotherapist-led Stress Inoculation Training integrated with exercise for acute whiplash injury. J Physiother. 2015;61:157.CrossRefPubMed
55.
Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7.CrossRefPubMedPubMedCentral
Metadata
Title
Pregabalin versus placebo in targeting pro-nociceptive mechanisms to prevent chronic pain after whiplash injury in at-risk individuals – a feasibility study for a randomised controlled trial
Authors
J. Nikles
G. Keijzers
G. Mitchell
S. Schug
R. Ware
S. A. McLean
L. Connelly
S. Gibson
S. F. Farrell
M. Sterling
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Trials / Issue 1/2018
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-018-2450-9

Other articles of this Issue 1/2018

Trials 1/2018 Go to the issue

Study protocol

FIT for FUNCTION: study protocol for a randomized controlled trial

Methodology

Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials

Study protocol

Photobiomodulation versus light-emitting diode (LED) therapy in the treatment of temporomandibular disorder: study protocol for a randomized, controlled clinical trial

Study protocol

Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial

Research

Patient understanding and acceptability of an early lung cancer diagnosis trial: a qualitative study

Study protocol

Pharm-MD; an open-label, randomized controlled, phase II study to evaluate the efficacy of a pharmacist-managed diabetes clinic in high-risk diabetes patients – study protocol for a randomized controlled trial